Design Therapeutics (Design Therapeutics (DSGN)) had a volatile Monday. Shares jumped in premarket trading after the company released promising data from its ongoing Phase 1/2 RESTORE-FA trial for DT-216P2, a drug aimed at treating Friedreich ataxia, a rare degenerative genetic disease. But by the end of the day, the stock had reversed course and was down nearly 29% at $10.22.
The data, announced Sunday, showed that the experimental GeneTAC small-molecule therapy produced dose-dependent increases in frataxin (FXN) levels and improved multiple clinical measures after just four weeks of treatment. Friedreich ataxia is caused by a deficiency of frataxin, a protein essential for mitochondrial function, so boosting it is the whole point.
As of May 17, 2026, 16 patients had completed weekly intravenous treatment across four dose cohorts ranging from 0.1 mpk to 1 mpk. The highest dose group showed a mean improvement of 6.4 points from baseline on the modified Friedreich's Ataxia Rating Scale (mFARS) after four weeks. That's a pretty big deal for a four-week trial in a disease that typically progresses slowly. The same cohort also showed a 2.7-point improvement in upright stability score and greater than five-point reductions in patient-reported fatigue scores, both after treatment and two weeks after the final dose. Design Therapeutics noted that these improvements exceeded the commonly recognized three-point threshold for meaningful fatigue changes.
On the biomarker side, DT-216P2 generated dose-dependent increases in FXN messenger RNA and protein levels in both blood and muscle tissue. At the 1 mpk dose, whole blood FXN mRNA levels increased 65% from baseline, while FXN protein levels rose between 22% and 27% two weeks after the last dose. Muscle FXN mRNA levels increased 42% from baseline. The drug was generally well tolerated, with no serious adverse events or treatment discontinuations reported. All adverse events were mild or moderate.
So why did the stock fall? It's not entirely clear from the data alone, but biotech stocks are notoriously volatile around clinical readouts. Sometimes the market expects more, or there's concern about the durability of the effect, or maybe investors were spooked by the small sample size. The company said it plans to pursue a registrational path for DT-216P2 and expects to provide an update on development plans during the fourth quarter of 2026. That's a long wait, and uncertainty might have weighed on the stock.
On Sunday, Design Therapeutics was among Jim Cramer's Mad Money stock calls, where he urged investors to exercise caution when it comes to red-hot AI stocks. That mention might have drawn some attention, but it's hard to say if it moved the stock.
Despite Monday's drop, DSGN has gained about 21% over the past month, compared to a 4% rise in the S&P 500, and is up roughly 67% year-to-date versus the index's 7.5% gain. So the stock has had a good run, and Monday's pullback could just be profit-taking or a reassessment of the risk-reward.
For now, the data look encouraging, but the road to approval is long. Design Therapeutics will need to confirm these results in larger, longer trials. Investors will be watching closely for the fourth-quarter update.
